Thierry Laugel is the managing partner of Kurma Life Science Partners. Thierry holds a PhD in pharmacology and an MBA from INSEAD.
After his dissertation, Thierry was a scientific representative for Laboratoires Fournier in Japan for four years at a time when Lipanthyl was released in Japan and research programmes were being rolled out with Grelan, a Takeda Group company.
He subsequently joined Flamel Technologies after its IPO on Nasdaq, as project director for Pharmaceutical R&D. In 1998, he moved to the investment world, firstly at CDC Innovation and then with AGF Private Equity, where he supervised the healthcare investment team.
He subsequently co-founded Kurma Life Sciences in 2008.